Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653956 | 0.82 | KCNJ6 (0.37) | LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17320995 | 0.75 | AURKA (0.35) | MAPTLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27739426 | 0.74 | MAPT (0.40) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL16050078 | 0.73 | MAPK1 (0.46) | GAAMAPTLMNACYP1A2ALDH1A1 | |
| SCHEMBL9608890 | 0.73 | GAA (0.44) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL26020948 | 0.72 | STING1 (0.38) | ALDH1A1 | |
| SCHEMBL21768349 | 0.71 | GAA (0.43) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL15746137 | 0.70 | GAA (0.42) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL27111156 | 0.70 | GAA (0.42) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL17320990 | 0.69 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | GAA 326/4885MAPT 635/4885LMNA 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.